BioAge Labs, Inc. has released interim results showing that its novel brain-penetrant NLRP3 inhibitor, BGE-102, was well-tolerated in early testing. Preliminary data suggests this once-daily oral medication could bring new options for conditions linked to inflammatory pathways.